CD22 and lymphoma: Arming NK-92 cells with high-affinity and specific CD22 ligands via glycan metabolic engineering or glycopolymer insertion, rather than CAR engineering, substantially improved their ability to bind and lyse CD22+ lymphoma cells in vitro and xenograft model [176].